Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients 18 years of age or older
Confirmed diagnosis of Multiple Myeloma
Stable renal function defined as two serum creatinine determinations of \< 3 mg/dL
Calculated creatinine clearance of greater than or equal to 30 mL/min
ECOG Performance Status of 0 or 1
Life expectancy of greater than or equal to 9 months
If the patient is of child-bearing potential, a negative pregnancy test is required at screening, while postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
Ability to comply with trial requirements and give informed consent.
You may not be if
IV Bisphosphonate therapy for more than 3 years.
Patients with a diagnosis of amyloidosis.
Known hypersensitivity to zoledronic acid or other bisphosphonates
Pregnant patients or lactating patients.
Women of childbearing potential not on a medically recognized form of contraception
Patients with uncontrolled cardiovascular disease, hypertension, and Type 2 diabetes mellitus.
Clareo Health | A Multiple Myeloma Trial in Patients With Bone Metastases
